Uses and Indications
Bystolic (nebivolol) is primarily indicated for the management of hypertension in adults. By blocking beta‑1 adrenergic receptors in the heart, nebivolol reduces heart rate and cardiac output, while its nitric oxide–mediated vasodilatory effect can reduce systemic vascular resistance. Clinicians prescribe Bystolic to lower elevated blood pressure and reduce the long‑term risks associated with uncontrolled hypertension, such as stroke, heart attack, and kidney damage. While it is not a first‑line option for every patient, nebivolol may be preferred for individuals who require a once‑daily beta‑blocker and for those who may benefit from its vasodilatory properties. In some cases, it is used off‑label in combination with other agents for patients needing multi‑drug blood pressure control, always based on clinician judgment.
Dosage and Administration
Bystolic is taken orally once daily, with or without food. The usual starting dose for most adults is 5 mg once daily. Depending on blood pressure response and tolerability, a clinician may lower the dose (for example to 2.5 mg) or increase it; many patients are titrated to 10 mg once daily when needed. Dose adjustments are recommended for select populations — for example, patients with moderate hepatic impairment generally start at a lower dose and require careful monitoring. Because nebivolol is metabolized by CYP2D6, genetic differences between patients can affect blood levels; clinicians may adjust dosing accordingly. Never change your dose without consulting the clinician who prescribed your medication. Follow blood pressure checks and recommended follow‑up intervals as directed to ensure the dose is both safe and effective.
Precautions and Warnings
Before starting Bystolic, review your complete medical history with a clinician, especially if you have heart conduction problems, severe bradycardia (slow heart rate), decompensated or severe heart failure, or a history of bronchospastic disease such as asthma. Beta‑blockers can exacerbate heart block, worsen overt heart failure, and cause significant slowing of the heart in susceptible individuals. Patients with diabetes should be counseled that beta‑blockers may mask symptoms of hypoglycemia (like rapid heart rate), so careful glucose monitoring is essential. Do not abruptly stop Bystolic without medical advice; sudden withdrawal can precipitate angina, myocardial infarction, or exacerbation of hypertension. Special caution is required in patients taking medications that reduce heart rate or atrioventricular conduction (e.g., certain calcium channel blockers), and in those with significant hepatic impairment where metabolism may be altered.
Contraindications
Bystolic should not be used in patients with known hypersensitivity to nebivolol or any component of the formulation. Avoid nebivolol in patients with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, cardiogenic shock, or overt decompensated cardiac failure requiring intravenous inotropic therapy. Use is also generally contraindicated in patients with severe hepatic impairment unless closely supervised by a specialist because of altered drug clearance. Individuals with a history of severe bronchospasm associated with beta‑blocker therapy should not receive nebivolol. Always inform your healthcare provider about all medical conditions before starting this medicine.
Possible Side Effects
Common side effects reported with nebivolol include fatigue, headache, dizziness, and nausea. Some patients experience bradycardia (slow heart rate) or hypotension (low blood pressure), particularly during dose titration or when combined with other blood pressure–lowering agents. Less frequently, patients may report sleep disturbances, peripheral coldness in the hands or feet, or reduced exercise tolerance. Rare but serious adverse events include symptomatic bradycardia, syncope, severe hypotension, and exacerbation of heart failure. If you experience chest pain, fainting, pronounced shortness of breath, or severe dizziness, seek immediate medical attention. Document and report any new or unusual symptoms to your clinician so they can assess whether dose adjustment or a different therapy is necessary.
Drug Interactions
Nebivolol interacts with a number of medications and substances. Concomitant use with other negative chronotropic agents — such as digoxin, verapamil, diltiazem, or certain antiarrhythmics — can produce additive effects on heart rate and atrioventricular conduction, increasing the risk of bradycardia or heart block. Strong CYP2D6 inhibitors (for example, fluoxetine, paroxetine, and quinidine) can raise nebivolol plasma concentrations, potentially increasing adverse effects; dose adjustments may be necessary. NSAIDs may blunt the antihypertensive effect of beta‑blockers. Combining nebivolol with other antihypertensive agents can enhance blood pressure lowering and increase the risk of symptomatic hypotension. Inform your clinician about all prescription and over‑the‑counter medications, herbal supplements, and recreational drugs you use to reduce the risk of harmful interactions.
Missed Dose
If you miss a dose of Bystolic, take it as soon as you remember on the same day. If it is almost time for your next scheduled dose, skip the missed dose and resume your usual dosing schedule—do not take two doses to make up for a missed dose. Doubling up increases the risk of excessive bradycardia and hypotension. If you frequently miss doses, discuss a dosing strategy with your clinician to improve adherence and maintain consistent blood pressure control.
Overdose Information
An overdose of nebivolol may cause severe bradycardia, hypotension, bronchospasm, hypoglycemia, and heart block. Management begins with supportive care: secure the airway, breathing, and circulation. For bradycardia, intravenous atropine is commonly used as first‑line therapy; if ineffective, consider temporary pacing or use of inotropic agents. Intravenous fluids and vasopressors may be required for hypotension. Glucagon can be considered for severe beta‑blocker overdose because it increases intracellular cyclic AMP independently of beta‑receptors. If ingestion is recent, activated charcoal may reduce absorption. In all suspected overdose cases, seek emergency medical attention or contact a poison control center immediately.
Storage and Handling
Store Bystolic tablets at room temperature, away from excessive heat, moisture, and direct light. Keep the medication in its original container and ensure the bottle is tightly closed. Protect medications from children and pets by storing them in a secure place. Do not use Bystolic after the expiration date printed on the label. If you have unused or expired tablets, follow local disposal guidelines or ask your pharmacy about safe medication disposal programs.
U.S. Prescription and Sale Information
In the United States, Bystolic is a prescription medication, and acquisition typically requires a prescription from a licensed clinician. Sunshine Pharmacy provides a legal and structured solution for acquiring Bystolic without requiring patients to present a traditional printed prescription at the point of sale. Through Sunshine Pharmacy’s platform, patients complete an online medical questionnaire and, when appropriate, are connected with a licensed clinician for telemedicine evaluation. If the clinician determines Bystolic is suitable and safe, they can issue an electronic prescription that Sunshine Pharmacy fills and ships in accordance with federal and state regulations. This process ensures patient safety, physician oversight, and legal compliance while increasing access and convenience for individuals managing hypertension.
Important Safety Information
Do not abruptly discontinue Bystolic without consulting your healthcare provider; sudden withdrawal may aggravate angina or precipitate a heart attack in susceptible patients. Notify your clinician if you experience signs of worsening heart failure (increased shortness of breath, swelling of the feet/legs, sudden weight gain), pronounced dizziness, fainting, or slow heart rate. Use with caution if you have diabetes, thyroid disorders, or peripheral vascular disease. Pregnant or breastfeeding women should discuss potential risks and benefits with their healthcare provider—beta‑blockers can affect the fetus or neonate. Always inform providers about all other medicines you take, including supplements. Report severe adverse reactions to your clinician or to the FDA MedWatch program.
Patient Information
What Bystolic does: Bystolic lowers blood pressure and helps reduce the risk of complications from long‑term hypertension. How to take it: Take Bystolic exactly as directed by your clinician, typically once daily. Do not chew or crush extended‑release formulations (follow instructions on the product). Monitor your blood pressure at home if advised and attend follow‑up visits so your clinician can adjust dosing. Lifestyle: Combine medication with lifestyle measures such as a heart‑healthy diet, regular physical activity, weight management, limiting alcohol, and quitting smoking for best results.
When to call your clinician: Contact your healthcare provider if you have symptoms of dangerously low blood pressure (dizziness, fainting), very slow heart rate, difficulty breathing, worsening heart failure symptoms, or signs of an allergic reaction (rash, swelling of face or throat). If you are pregnant, planning pregnancy, or breastfeeding, inform your prescribing clinician before starting or continuing nebivolol.
Access through Sunshine Pharmacy: For patients seeking a convenient and responsible route to Bystolic, Sunshine Pharmacy offers an online consultation and clinician review that leads to a lawful electronic prescription when appropriate. This telemedicine pathway is intended to ensure that treatment is clinically appropriate, to screen for contraindications and interactions, and to provide counseling on safe use. If approved, medications are dispensed and shipped with counseling materials and follow‑up instructions so patients receive both the drug and the clinical support needed for safe, effective treatment.
Bystolic is the brand name for nebivolol, an oral beta-1 selective blocker used mainly to treat high blood pressure; unlike many older beta-blockers, nebivolol also promotes nitric oxide–mediated vasodilation.
It reduces heart rate and cardiac output by blocking beta-1 receptors and causes peripheral vasodilation via nitric oxide pathways, which together lower systemic blood pressure.
Bystolic is primarily approved for hypertension; clinicians may use beta-blockers for other cardiovascular indications, but nebivolol’s main labeled use is blood pressure control.
Typical starting dose for adults is 5 mg once daily, with common dose adjustments to 2.5–10 mg daily based on blood pressure response and tolerability; dose recommendations may vary by region and patient factors.
Blood-pressure lowering can be seen within hours, but full antihypertensive effect usually becomes apparent over days to weeks; nebivolol is dosed once daily because of its sustained duration of action.
Common side effects include headache, fatigue, dizziness, and nausea; because it is beta-1 selective, traditional beta-blocker effects like bronchospasm or marked cold extremities may occur less frequently but are still possible.
Serious contraindications include severe bradycardia, uncontrolled heart block (second- or third-degree without a pacemaker), cardiogenic shock, and decompensated heart failure; use cautiously in patients with diabetes, peripheral vascular disease, or reactive airway disease.
Nebivolol is relatively beta-1 selective and may pose less risk of bronchospasm than nonselective beta-blockers, but any beta-blocker can worsen reactive airway disease, so use only with caution and under medical supervision in asthma/COPD.
Nebivolol may have a lower incidence of sexual dysfunction and fatigue for some patients compared with certain older beta-blockers, but individual responses vary and those side effects can still occur.
Do not stop Bystolic abruptly; taper gradually under medical guidance because abrupt withdrawal of beta-blockers can precipitate angina, myocardial infarction, or rebound hypertension.
Yes—CYP2D6 inhibitors can raise nebivolol levels; other heart rate–lowering drugs (like verapamil, diltiazem, digoxin, or other beta-blockers) increase risk of bradycardia or heart block; always review medications with a clinician or pharmacist.
Data are limited; beta-blockers can affect fetal growth and neonatal heart rate and glucose in some cases, so nebivolol should be used in pregnancy or breastfeeding only if clearly needed and supervised by a clinician.
Baseline heart rate and blood pressure should be documented and periodically monitored; additional testing may be required based on comorbidities, but routine blood tests specific to nebivolol are not usually required.
People with diabetes can take nebivolol, and beta-1 selective agents may have less adverse effect on glucose metabolism than nonselective agents, but beta-blockers can mask signs of hypoglycemia (like tachycardia), so careful monitoring is necessary.
Nebivolol is available as a generic in many countries; generic formulations approved by regulatory agencies contain the same active ingredient and should have comparable efficacy and safety, though cost and availability vary.
Take Bystolic once daily at the same time each day, with or without food; do not skip doses and follow up with your clinician to adjust dose as needed.
Both lower blood pressure by beta-1 blockade, but nebivolol adds nitric oxide–mediated vasodilation, which may improve endothelial function and reduce peripheral resistance; nebivolol is often associated with fewer reports of fatigue and sexual side effects, though individual outcomes differ.
Both are beta-1 selective, but nebivolol’s nitric oxide–mediated vasodilation can offer additional vascular benefits and sometimes better tolerability; atenolol is less commonly preferred because of less favorable pharmacokinetics and outcome data in some studies.
Propranolol is nonselective and blocks beta-2 receptors in the lungs, raising bronchospasm risk; nebivolol is beta-1 selective and generally safer for patients with mild reactive airway disease, but caution is still warranted.
Carvedilol blocks beta-1, beta-2, and alpha-1 receptors and has proven mortality benefit in heart failure; nebivolol is beta-1 selective with vasodilatory effects and may be better tolerated for blood pressure control, but carvedilol is often preferred when treating systolic heart failure.
Bisoprolol and nebivolol are both beta-1 selective; nebivolol is extensively metabolized by CYP2D6 and has variable half-life in poor metabolizers, while bisoprolol has more predictable pharmacokinetics; dosing and patient factors guide choice.
Labetalol (alpha and beta blocker) is commonly used in pregnancy and has extensive safety data; nebivolol has limited pregnancy data, so labetalol is typically preferred for pregnancy-related hypertension unless a clinician advises otherwise.
Nebivolol lowers heart rate comparably to other beta-1 blockers, though the vasodilatory effect may allow effective blood-pressure control without requiring as large a heart-rate reduction in some patients.
Older nonselective agents and some older beta-1 selective drugs have been more commonly linked to sexual dysfunction; nebivolol tends to have a lower reported incidence, but individual responses vary and absolute risk differences are modest.
Potential advantages include improved tolerability (less fatigue, fewer sexual side effects) and added vasodilation, which may help patients whose blood pressure remains uncontrolled or who experience side effects on other beta-blockers, but any switch should be supervised by a clinician.
Both require monitoring for bradycardia and hypotension; carvedilol’s alpha-blocking effect can cause orthostatic symptoms, so when switching to nebivolol expect a different hemodynamic profile and adjust doses gradually with clinical monitoring.
Some studies suggest nebivolol may be associated with less exercise intolerance and fatigue due to its vasodilatory action, but results vary and patient-specific factors determine real-world differences.
Nebivolol’s metabolism via CYP2D6 makes it susceptible to interactions with strong CYP2D6 inhibitors; other beta-blockers have different metabolic pathways (e.g., metoprolol via CYP2D6 as well, atenolol renally excreted), so interaction profiles differ by agent.
Switching to a generic beta-blocker may be reasonable for cost reasons, but since effects, side effects, and metabolic profiles vary among agents, discuss with your clinician before switching to ensure the alternative fits your medical needs.
Carvedilol and bisoprolol have strong evidence for mortality benefit in systolic heart failure; nebivolol has less extensive outcome data in this setting, so substitution should not be made without specialist input and consideration of guideline recommendations.
Yes—factors like comorbid respiratory disease, metabolic profile, drug interactions, renal/hepatic function, pregnancy status, tolerance of side effects, and evidence for disease-specific outcomes should guide the choice.
Nebivolol’s nitric oxide–mediated vasodilation has been associated in studies with improved endothelial function relative to some other beta-blockers, which might be beneficial for vascular health, though clinical significance varies.
Discuss any proposed change with your prescribing clinician or pharmacist, who can review your medical history, current medications, and monitoring plan to make a safe and effective transition.
